Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
Creative Medical reported a 93% response rate in a pilot study of Ultrasome, a cell-free regenerative therapy for knee osteoarthritis, with no serious adverse events. Derived from the company's CELZ-201 platform, Ultrasome aims to offer scalable, off-the-shelf treatment targeting a multi-billion dollar market affecting over 30 million U.S. adults.
Key figures
- Drug Name
- Ultrasome™
- Phase Of Trial
- pilot study
- Response rate
- 93%
- Patients affected market
- 30 million adults
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.